http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 25 Mar 2026 08:00:46 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html <p>LakeShore Biopharma Co., Ltd. (OTCPK: LSBCF; OTCPK: LSBWF) announced that its special board committee received a revised preliminary non-binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire outstanding shares for $0.06 per ordinary share.</p> <p>The revised proposal reduces the purchase price from an original merger agreement dated November 4, 2025. The acquirers cited arbitral awards issued by the Kaifeng Arbitration Commission on January 21 and January 22, 2026, which ordered certain Chinese subsidiaries of LakeShore to pay approximately RMB576.5 million in financial liabilities.</p> <p>Oceanpine stated the awards constitute a "Company Material Adverse Effect" under the original merger agreement, http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html Wed, 25 Mar 2026 08:00:46 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html <p>LakeShore Biopharma Co., Ltd. (OTCPK: LSBCF; OTCPK: LSBWF) announced that its special board committee received a revised preliminary non-binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire outstanding shares for $0.06 per ordinary share.</p> <p>The revised proposal reduces the purchase price from an original merger agreement dated November 4, 2025. The acquirers cited arbitral awards issued by the Kaifeng Arbitration Commission on January 21 and January 22, 2026, which ordered certain Chinese subsidiaries of LakeShore to pay approximately RMB576.5 million in financial liabilities.</p> <p>Oceanpine stated the awards constitute a "Company Material Adverse Effect" under the original merger agreement, http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html Wed, 25 Mar 2026 08:00:46 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html <p>LakeShore Biopharma Co., Ltd. (OTCPK: LSBCF; OTCPK: LSBWF) announced that its special board committee received a revised preliminary non-binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire outstanding shares for $0.06 per ordinary share.</p> <p>The revised proposal reduces the purchase price from an original merger agreement dated November 4, 2025. The acquirers cited arbitral awards issued by the Kaifeng Arbitration Commission on January 21 and January 22, 2026, which ordered certain Chinese subsidiaries of LakeShore to pay approximately RMB576.5 million in financial liabilities.</p> <p>Oceanpine stated the awards constitute a "Company Material Adverse Effect" under the original merger agreement, http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html Wed, 25 Mar 2026 08:00:46 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html <p>LakeShore Biopharma Co., Ltd. (OTCPK: LSBCF; OTCPK: LSBWF) announced that its special board committee received a revised preliminary non-binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire outstanding shares for $0.06 per ordinary share.</p> <p>The revised proposal reduces the purchase price from an original merger agreement dated November 4, 2025. The acquirers cited arbitral awards issued by the Kaifeng Arbitration Commission on January 21 and January 22, 2026, which ordered certain Chinese subsidiaries of LakeShore to pay approximately RMB576.5 million in financial liabilities.</p> <p>Oceanpine stated the awards constitute a "Company Material Adverse Effect" under the original merger agreement, http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html Wed, 25 Mar 2026 08:00:46 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html <p>LakeShore Biopharma Co., Ltd. (OTCPK: LSBCF; OTCPK: LSBWF) announced that its special board committee received a revised preliminary non-binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire outstanding shares for $0.06 per ordinary share.</p> <p>The revised proposal reduces the purchase price from an original merger agreement dated November 4, 2025. The acquirers cited arbitral awards issued by the Kaifeng Arbitration Commission on January 21 and January 22, 2026, which ordered certain Chinese subsidiaries of LakeShore to pay approximately RMB576.5 million in financial liabilities.</p> <p>Oceanpine stated the awards constitute a "Company Material Adverse Effect" under the original merger agreement, http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+receives+revised+%240.06+per+share+buyout+proposal/26213444.html Wed, 25 Mar 2026 08:00:46 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>March 25, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated <chron>March 24, 2026</chron>, from <span>Oceanpine Skyline Inc.</span> ("Parent") and <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), to reduce the purchase price http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+a+Revised+Preliminary+Non-Binding+Proposal+to+Acquire+the+Company/26213380.html Wed, 25 Mar 2026 08:00:00 -0400 A.12939998 LSBCF LSBWF O.20113046 O.50653405 http://www.streetinsider.com/Corporate+News/LakeShore+Biopharma+postpones+shareholder+meeting+amid+merger+dispute/25957928.html <p>LakeShore Biopharma Co., Ltd. (OTCPK: LSBCF) postponed its extraordinary general meeting of shareholders scheduled for February 12, 2026, after a buyer group indicated it would not complete the previously announced $0.90 per share going-private transaction.</p><p>The buyer group, which includes Oceanpine Skyline Inc., Oceanpine Capital Inc., and several investment funds, sent notice on February 4, 2026, asserting that arbitral awards received by LakeShore constitute a "Company Material Adverse Effect" under the merger agreement signed November 4, 2025.</p><p>The Kaifeng Arbitration Commission issued awards to LakeShore on January 21 and January 22, 2026, resulting in a financial liability of approximately RMB576.5 million ($79.8 http://www.streetinsider.com/Corporate+News/LakeShore+Biopharma+postpones+shareholder+meeting+amid+merger+dispute/25957928.html Fri, 06 Feb 2026 07:05:46 -0400 LSBCF LSBWF http://www.streetinsider.com/Corporate+News/LakeShore+Biopharma+postpones+shareholder+meeting+amid+merger+dispute/25957928.html <p>LakeShore Biopharma Co., Ltd. (OTCPK: LSBCF) postponed its extraordinary general meeting of shareholders scheduled for February 12, 2026, after a buyer group indicated it would not complete the previously announced $0.90 per share going-private transaction.</p><p>The buyer group, which includes Oceanpine Skyline Inc., Oceanpine Capital Inc., and several investment funds, sent notice on February 4, 2026, asserting that arbitral awards received by LakeShore constitute a "Company Material Adverse Effect" under the merger agreement signed November 4, 2025.</p><p>The Kaifeng Arbitration Commission issued awards to LakeShore on January 21 and January 22, 2026, resulting in a financial liability of approximately RMB576.5 million ($79.8 http://www.streetinsider.com/Corporate+News/LakeShore+Biopharma+postpones+shareholder+meeting+amid+merger+dispute/25957928.html Fri, 06 Feb 2026 07:05:46 -0400 LSBCF LSBWF http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+postpones+shareholder+meeting+amid+merger+dispute/25957928.html <p>LakeShore Biopharma Co., Ltd. (OTCPK: LSBCF) postponed its extraordinary general meeting of shareholders scheduled for February 12, 2026, after a buyer group indicated it would not complete the previously announced $0.90 per share going-private transaction.</p><p>The buyer group, which includes Oceanpine Skyline Inc., Oceanpine Capital Inc., and several investment funds, sent notice on February 4, 2026, asserting that arbitral awards received by LakeShore constitute a "Company Material Adverse Effect" under the merger agreement signed November 4, 2025.</p><p>The Kaifeng Arbitration Commission issued awards to LakeShore on January 21 and January 22, 2026, resulting in a financial liability of approximately RMB576.5 million ($79.8 http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+postpones+shareholder+meeting+amid+merger+dispute/25957928.html Fri, 06 Feb 2026 07:05:46 -0400 LSBCF LSBWF http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+postpones+shareholder+meeting+amid+merger+dispute/25957928.html <p>LakeShore Biopharma Co., Ltd. (OTCPK: LSBCF) postponed its extraordinary general meeting of shareholders scheduled for February 12, 2026, after a buyer group indicated it would not complete the previously announced $0.90 per share going-private transaction.</p><p>The buyer group, which includes Oceanpine Skyline Inc., Oceanpine Capital Inc., and several investment funds, sent notice on February 4, 2026, asserting that arbitral awards received by LakeShore constitute a "Company Material Adverse Effect" under the merger agreement signed November 4, 2025.</p><p>The Kaifeng Arbitration Commission issued awards to LakeShore on January 21 and January 22, 2026, resulting in a financial liability of approximately RMB576.5 million ($79.8 http://www.streetinsider.com/Mergers+and+Acquisitions/LakeShore+Biopharma+postpones+shareholder+meeting+amid+merger+dispute/25957928.html Fri, 06 Feb 2026 07:05:46 -0400 LSBCF LSBWF http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Feb. 6, 2026</chron></span> /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated <chron>February 4, 2026</chron>, from legal counsel to a group (the "Buyer Group") consisting of <span>Oceanpine Skyline Inc.</span> ("Parent"), <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), <span>Oceanpine Capital Inc.</span>, <span>Oceanpine Investment Fund II LP</span>, <span>Crystal Peak Investment Inc.</span>, <span>Adjuvant Global Health Technology Fund, http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html Fri, 06 Feb 2026 07:00:00 -0400 LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Feb. 6, 2026</chron></span> /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated <chron>February 4, 2026</chron>, from legal counsel to a group (the "Buyer Group") consisting of <span>Oceanpine Skyline Inc.</span> ("Parent"), <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), <span>Oceanpine Capital Inc.</span>, <span>Oceanpine Investment Fund II LP</span>, <span>Crystal Peak Investment Inc.</span>, <span>Adjuvant Global Health Technology Fund, http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html Fri, 06 Feb 2026 07:00:00 -0400 LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Feb. 6, 2026</chron></span> /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated <chron>February 4, 2026</chron>, from legal counsel to a group (the "Buyer Group") consisting of <span>Oceanpine Skyline Inc.</span> ("Parent"), <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), <span>Oceanpine Capital Inc.</span>, <span>Oceanpine Investment Fund II LP</span>, <span>Crystal Peak Investment Inc.</span>, <span>Adjuvant Global Health Technology Fund, http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html Fri, 06 Feb 2026 07:00:00 -0400 LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Feb. 6, 2026</chron></span> /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated <chron>February 4, 2026</chron>, from legal counsel to a group (the "Buyer Group") consisting of <span>Oceanpine Skyline Inc.</span> ("Parent"), <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), <span>Oceanpine Capital Inc.</span>, <span>Oceanpine Investment Fund II LP</span>, <span>Crystal Peak Investment Inc.</span>, <span>Adjuvant Global Health Technology Fund, http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html Fri, 06 Feb 2026 07:00:00 -0400 LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Feb. 6, 2026</chron></span> /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated <chron>February 4, 2026</chron>, from legal counsel to a group (the "Buyer Group") consisting of <span>Oceanpine Skyline Inc.</span> ("Parent"), <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), <span>Oceanpine Capital Inc.</span>, <span>Oceanpine Investment Fund II LP</span>, <span>Crystal Peak Investment Inc.</span>, <span>Adjuvant Global Health Technology Fund, http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html Fri, 06 Feb 2026 07:00:00 -0400 LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Feb. 6, 2026</chron></span> /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("<span value="OTC-PINK:LSBCF" idsrc="xmltag.org" >LakeShore Biopharma</span>" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated <chron>February 4, 2026</chron>, from legal counsel to a group (the "Buyer Group") consisting of <span>Oceanpine Skyline Inc.</span> ("Parent"), <span>Oceanpine Merger Sub Inc.</span> ("Merger Sub"), <span>Oceanpine Capital Inc.</span>, <span>Oceanpine Investment Fund II LP</span>, <span>Crystal Peak Investment Inc.</span>, <span>Adjuvant Global Health Technology Fund, http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+Buyer+Group+Notice+and+Postponement+of+Extraordinary+General+Meeting+of+Shareholders/25957863.html Fri, 06 Feb 2026 07:00:00 -0400 LSBCF LSBWF LSBWF O.50653405